Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance

USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ

(2020) Hong Zhu et al.   CANCER RESEARCH

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade

(2020) Tsung-Hao Liu et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

(2020) Michael S Lee et al.   LANCET ONCOLOGY

Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma

(2020) Furong Liu et al.   Experimental Hematology & Oncology

The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China

(2020) Yanhui Chen et al.   Experimental Hematology & Oncology

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

(2019) Ming Yi et al.   Molecular Cancer

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases

(2012) Yu-Yun Shao et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION